EP Patent

EP2780353B1 — Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases

Assigned to Alnylam Pharmaceuticals Inc · Expires 2017-08-16 · 9y expired

What this patent protects

Patent listed against vutrisiran-sodium.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: EP2780353B1
Jurisdiction: EP
Classification: —
Expires: 2017-08-16
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.